• Reduced transfusion reactions

  • Avoided bacterial detection

  • Reduced platelet expiry as a result of extended storage

  • Providing proactive protection against emerging pathogens

  • Provide pathogen protection for platelets consistent with that afforded to plasma products

Collection Platform:
Amicus (Fenwal)

Platelet Suspension Medium:
PAS - InterSol (Fenwal)

INTERCEPT Disposable Set:
INT2103B

Separation Platform:
Compomat G4 (Fresenius)
Orbisac (CaridianBCT)

Platelet Suspension Medium:
PAS - InterSol (Fenwal)

INTERCEPT Disposable Set:
INT2203B

 

Customer Profile: Blood Transfusion Center of Slovenia

Date of INTERCEPT Implementation
2009: Apheresis & Buffy Coat Platelets

Annual Collections

• 58,108 whole blood donations
• 1,248 apheresis donations


Annual INTERCEPT Production
• 3,618 units of platelet concentrates
(partial year, June thru December 2009)

www.ztm.si


Center Profile
The Blood Transfusion Center of Slovenia located in Ljubljana is part of the Slovenian Blood Transfusion Service (BTCS/ZTM) and serves as the national reference center for the country. The BTCS/ZTM coordinates and monitors all activities related to donor selection, collection, testing, processing, storage, and distribution of blood and blood components for Slovenia. The BTCS provides blood components for public hospitals and private clinics, including the Oncology Institute of Ljubljana.

Production Lab
INTERCEPT processing at the BTCS requires less than 25m2. The blood center takes advantage of the stackable design of the INTERCEPT illuminator to reduce the overall space requirements for treatment. The illuminators include a tray-tilt feature which facilitates loading and unloading of products into the upper illuminator, as well as routine cleaning. Locating the INTERCEPT treatment room proximate to the platelet preparation room maximizes the center’s efficiency.

INTERCEPT Workflow
The BTCS INTERCEPT treats both apheresis and buffy coat platelets. As depicted below, collections generally occur in the morning and early afternoon. Apheresis platelets undergo pathogen inactivation the same day as collection. Platelets prepared via the buffy coat method are pooled and INTERCEPT treated on Day 1.

INTERCEPT Validation Results
Prior to implementing INTERCEPT in routine use, the BTCS validated the treatment process in their center for both apheresis and buffy coat platelets. The results met local requirements for suitable transfusion products. The BTCS now pathogen inactivates 100% of their platelet units with the INTERCEPT Blood System.

Table 1: BTC of Slovenia Validation Results for
INTERCEPT Platelets (Apheresis)a
Parameter
INTERCEPT Platelets
Average (Range)
N
Volume (mL)
282 (270–290)
17
Platelet count (x1011 plt/unit)
2.76 (2.32–3.10)
17
pH (day7)
6.90 (6.70–7.08)
17
Post-CAD residual amotosalen (μM)
0.37 (0.25–0.50)
17
a. Volume and platelet counts are post PI.

Table 2: BTC of Slovenia Validation Results for
INTERCEPT Platelets (Buffy Coat)a
Parameter
INTERCEPT Platelets
Average (Range)
N
Volume (mL)
362 (344–378)
28
Platelet count (x1011 plt/unit)
3.29 (2.54–3.29)
28
pH (day7)
7.00 (6.77–7.14)
28
Post-CAD residual amotosalen (μM)
0.66 (0.45–1.02)
28
a. Volume and platelet counts are post PI.